Best Exercise for Fatty Liver? It Depends on the Outcome

The best exercise for fatty liver depends on what you want to improve. For cardiorespiratory fitness, exercise has a convincing edge. For liver fat—the disease-defining feature of metabolic dysfunction-associated steatotic liver disease (MASLD)—the evidence supports exercise overall but does not yet justify a confident winner between aerobic training, resistance work, and high-intensity intervals.

That distinction gets lost when "exercise helps fatty liver" becomes "HIIT is best for fatty liver." Those are different claims, measured with different endpoints. A program can deliver a large increase in VO2max without proving that it reduces intrahepatic lipid more than another program. Your liver, regrettably, does not award points for a particularly impressive interval timer.

Exercise is a reliable treatment for fitness and several cardiometabolic risk markers in MASLD. A sharp modality hierarchy for liver fat remains less secure.

The biggest quantified benefit is fitness, not liver fat

A 2025 systematic review and meta-analysis by Chen et al. pooled 29 randomized controlled trials involving 1,123 overweight or obese people with MASLD. The interventions included exercise of any type compared with control conditions. The largest pooled effect was for VO2max, a measure of cardiorespiratory fitness: standardized mean difference (SMD) 0.75, with p<0.001.

The same analysis found statistically significant improvements in waist circumference (SMD −0.41), diastolic blood pressure (SMD −0.38), and BMI (SMD −0.28), all with p<0.001. Body-fat percentage moved in the favorable direction but did not reach conventional statistical significance: SMD −0.25, p=0.061.

Those results make a practical point. A sustained exercise habit has a strong rationale in MASLD even before discussing liver-specific outcomes. Better fitness and lower waist circumference matter to cardiometabolic health. But Chen et al. did not measure intrahepatic lipid (IHL). It therefore cannot tell us which exercise modality lowers liver fat most effectively.

Waist circumference may change before total body-fat percentage

The combination of a significant waist reduction and a non-significant change in total body-fat percentage does not prove that exercise strips visceral or liver fat first. It does show that these measurements are not interchangeable. Waist circumference tracks central adiposity more closely than a whole-body percentage, while body-fat percentage includes subcutaneous fat that may be metabolically less relevant.

This pattern is consistent with a shift in central or ectopic fat depots that a total-body measure may miss, but it is still an inference rather than a demonstrated sequence of fat loss. The measurement problem matters in MASLD because neither bioelectrical impedance nor standard body-composition measures can identify liver fat. Even liver-fat research faces comparability problems: MRI-PDFF, proton magnetic resonance spectroscopy, and ultrasound grading do not measure steatosis in identical ways. A 2022 imaging study by Park et al. also documented variation in MRI-PDFF diagnostic cutoffs, which adds noise when trials are pooled.

Liver-fat rankings need liver-fat studies

For the central MASLD endpoint, the relevant evidence comes from trials and meta-analyses that measured IHL directly. A 2025 network meta-analysis by Khalafi et al. compared aerobic exercise, resistance training, HIIT, and combined training for IHL, glucose homeostasis, and liver function in adults with and without NAFLD. A 2024 network meta-analysis by Huang et al. compared exercise modalities for metabolic measures and liver enzymes, including ALT and AST, in NAFLD.

These analyses are much better suited to the question "what lowers liver fat?" than the larger Chen review. Yet their available reports do not provide sufficiently extractable modality-specific IHL estimates to state a precise ranking here. That is not a minor reporting inconvenience. Without the effect size, uncertainty interval, and direct comparison for each modality, declaring aerobic exercise, HIIT, resistance training, or combined training the universal champion would exceed the evidence.

Huang et al. cite background evidence that sustained exercise can reduce hepatic fat by 20% to 30% independent of weight loss. That supports the broader conclusion that exercise can improve liver fat even without dramatic scale changes. It does not establish that any one training format reliably produces that reduction in every person, or that a reduction in imaging-measured fat guarantees histologic resolution or lower liver-related clinical events.

HIIT has a place, but no proven monopoly on liver outcomes

HIIT often gets special attention because it can improve fitness efficiently, but the liver-specific case is more restrained. A 2022 systematic review and meta-analysis by Sabag et al. directly examined HIIT versus moderate-intensity continuous training (MICT) for liver fat. A 2025 HIIT-focused meta-analysis by Fu et al. assessed clinical parameters in people with MASLD.

Most relevant to the sales pitch for intervals, a 2024 direct comparison by Guo et al. found HIIT and traditional aerobic training equivalent on liver-relevant biochemical outcomes in people with NAFLD. Liver enzymes are imperfect surrogates for liver fat and do not answer every hepatic question, but this head-to-head result does weaken claims that HIIT is clearly superior for liver biochemistry.

HIIT may still be an excellent choice for someone who enjoys it, can perform it safely, and keeps doing it. Traditional aerobic training remains equally defensible when the aim is liver biochemical improvement. The evidence does not provide modality-specific dropout rates across the relevant comparisons, so it cannot yet show whether a theoretical advantage for higher intensity survives real-world adherence.

For steatosis resolution and fibrosis, diet changes the equation

The strongest practical recommendation is not a special workout. It is a program that combines activity with dietary change and produces meaningful weight loss. A 2025 systematic review and meta-analysis by Artola Arita et al. of randomized trials in MASLD reported that a 7% to 10% reduction in body weight through a Mediterranean diet and exercise intervention was associated with steatosis resolution, reduced inflammation, and fibrosis regression.

Exercise alone may improve fitness, waist size, blood pressure, and liver fat without reliably reaching that weight-loss range. The same evidence does not establish that exercise alone consistently achieves the 7% to 10% threshold. A 2025 meta-analysis and meta-regression by Kazeminasab et al. found that combining exercise training with dietary restriction reduced ectopic fat more than exercise alone in people with overweight or obesity. The analysis isolated an additional dietary contribution, although it cannot fully separate a liver-specific dietary effect from the benefit of greater total weight loss.

For a person with MASLD who wants histologic improvement rather than only better fitness, that distinction is decisive. Exercise belongs in the treatment plan, but caloric intake and dietary quality usually determine whether the program reaches the weight-loss range linked with steatosis and fibrosis outcomes.

Why the evidence should make you cautious

Exercise trials in this area commonly last 8 to more than 24 weeks and vary in frequency, session duration, and intensity. Reported programs span roughly three to five sessions per week, 30 to 60 minutes per session, and 50% to 85% of VO2max. That variation prevents a reliable dose-response prescription for IHL reduction.

Many individual randomized trials also enroll only about 20 to 60 participants per arm. Small trials can produce unstable estimates, while network meta-analyses depend on whether their included studies, outcome measures, and indirect comparisons fit together well enough to compare modalities fairly. Publication bias is another concern because trials with null liver-fat findings may be less likely to appear in the literature.

The 2021 Cochrane network meta-analysis by Buzzetti et al. provides an appropriately conservative counterweight. Its stricter handling of bias and uncertainty means modality differences should not be treated as settled merely because a newer pooled analysis produces a tidy ranking. The current literature supports exercise as treatment; it does not yet support treating an exercise leaderboard as a clinical guideline.

What to do with this evidence

• For fitness and cardiovascular risk markers: choose a sustainable exercise program. Across 29 RCTs in overweight or obese people with MASLD, exercise produced its largest pooled benefit in VO2max and also reduced waist circumference, diastolic blood pressure, and BMI.
• For liver fat: aerobic exercise, HIIT, resistance training, and combined programs all belong in the evidence base, but the available quantitative comparisons do not establish one universal winner. HIIT has not shown clear superiority over traditional aerobic training for liver biochemical outcomes.
• For steatosis resolution, inflammation reduction, or fibrosis regression: pair exercise with dietary change and target 7% to 10% body-weight loss. That is the evidence-supported path to the liver outcomes that matter most.

The best program is the one that matches the endpoint and can continue long enough to matter. If the immediate target is fitness, exercise works. If the target is liver histology, exercise needs dietary backup and enough weight loss to reach the range studied.